Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ZP1848
DRUG
2 trials
Sponsors
Zealand Pharma
Conditions
Inflammatory Bowel Disease
Short Bowel Syndrome
Phase 1
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
Completed
NCT00868660
Zealand Pharma
Inflammatory Bowel Disease
Start: 2009-01-31
End: 2010-02-28
Updated: 2010-11-02
Phase 2
A Phase 2 Trial Testing ZP1848 in Patients With SBS
Completed
NCT02690025
Zealand Pharma
Short Bowel Syndrome
Start: 2016-02-29
End: 2017-05-31
Updated: 2017-06-21
Related Papers
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.
2019-07-17
21 citations
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
2019-03-15
54 citations